FTC Approves Novartis' $16B GSK Oncology Buy With Fixes
The Federal Trade Commission on Monday signed off on Novartis AG's $16 billion acquisition of GlaxoSmithKline PLC's oncology business on the condition that Swiss pharmaceutical giant shed certain skin cancer drugs,...To view the full article, register now.
Already a subscriber? Click here to view full article